FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps: NYT (Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday. The FDA is expected to […]

Drugmakers should test any Covid-19 vaccines that have been retooled to combat new variants of the coronavirus in clinical trials designed to track the immune response of hundreds of subjects, which could take months, U.S. regulators said on Feb. 22.

U.S. President Joe Biden secured a commitment from Pfizer Inc. to double the Covid-19 vaccine the company churns out in the coming weeks, putting his goal to fill the country’s inoculation stockpile by summer in sight.

Pfizer Inc. and BioNTech SE asked the U.S. health regulator to relax requirements for their Covid-19 vaccine to be stored at ultra-low temperatures, potentially allowing for it to be kept in pharmacy freezers.

Pfizer’s Covid-19 vaccine greatly reduces virus transmission, according to two Israeli studies, shedding light on one of the biggest questions of the global effort to quash the pandemic.

Pfizer Inc. and BioNTech SE started an international study with 4,000 volunteers to evaluate the safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.

With distribution of Covid-19 vaccines being slow, public health officials and researchers are trying to develop schemes and rationales for delaying the dosing of the second shots of the Pfizer-BioNTech and Moderna vaccines – with the first shots being highly effective – allowing the current limited vaccine supply to be given to more people.

South Korea’s intelligence agency said North Korea attempted to steal information on coronavirus vaccines and treatments by hacking Pfizer Inc., a lawmaker briefed by the agency said.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.

Israel’s largest healthcare provider reported a 94% drop in symptomatic Covid-19 infections among 600,000 people who received two doses of Pfizer’s vaccine in the country’s biggest study to date.